Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

Background In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease (‘trastuzumab-free interval’, TFI) is crucial to choose the optimal first-line treatment. Nevertheless, there is no clear evidence to support its possible progn...

Full description

Bibliographic Details
Main Authors: Francesca Poggio, Lucia Del Mastro, Florentine S Hilbers, Saranya Chumsri, Noam F Pondé, Dominique Agbor-Tarh, Otto Metzger-Filho, Larissa A Korde, Olena Werner, Volker Moebus, Alvaro Moreno-Aspitia, Martine J Piccart
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/6/e000979.full

Internet

https://esmoopen.bmj.com/content/5/6/e000979.full

Similar Items